Navigation Links
NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
Date:4/16/2008

NEW YORK, April 16 /PRNewswire/ -- NexGenix Pharmaceuticals, presented data on its Hsp90 inhibitor program today at the Annual Meeting of the AACR in San Diego today. The company presented data in the experimental therapeutics session on NXD30001, one of several novel, radicicol-based Hsp90 inhibitors in its compound series.

NXD30001 demonstrated efficacy in breast cancer tumor xenograft models without evidence for liver and kidney toxicity. The potency, tolerability, pharmacokinetic and pharmacodynamic properties of NXD30001 and its derivatives indicate that it, or an analog, may be useful in the treatment of breast and other forms of cancer with an improved dosing and therapeutic window compared to 17AAG, the first-in-class Hsp90 inhibitor currently in Phase 2 clinical trials for cancer.

The compound series appears to bind Hsp90 in a different mode than 17AAG or radicicol and exhibit higher affinity to Hsp90 than radicicol. NXD30001 and its analogs efficiently inhibit cell proliferation and deplete multiple Hsp90 client proteins such as Her2, Akt, c-Raf, Cdk4, and Cyclin D1 in Her2-overexpressing breast and other cancer cell lines at low nanomolar concentrations. Pharmacokinetic studies demonstrate that NXD30001 can achieve potential therapeutic levels via intraperitoneal (i.p.) dosing and that the compound accumulates in tumors at above micromolar concentrations.

Tumor pharmacodynamic analysis demonstrated depletion of multiple Hsp90 client proteins, including Her2, after a single dose; these client proteins remained undetectable for more than 2 days, consistent with the pharmacokinetic tumor data.

"A number of analogs with activity similar to or better than NXD30001 have been synthesized and are being evaluated for oral bioavailability, tolerability, and efficacy," stated Allan Rubenstein, MD, CEO of NexGenix. "Our intent is to progress an i.v. formulation of NXD30001 into IND-enabling studies for breast cancer, and to develop
'/>"/>

SOURCE NexGenix Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... June 20, 2013 New ... technology solutions for pharmaceutical and chemical sectors ... Manufacturing Pte. Ltd. and Siemens Pte. Ltd, have ... A*STAR R&D Consortium Programme - Innovative Processing of ... of Chemical and Engineering Sciences (ICES), the consortium ...
(Date:6/19/2013)... June 19, 2013 Bellevue city ... hall of technology solutions for people with disabilities ... Hyatt Regency Bellevue. , The exhibit hall, ... on Saturday and Sunday, will feature leading manufacturers ... wheelchairs, communication devices, eyegaze technologies, computer applications, and ...
(Date:6/19/2013)... 2013  U.S. Secretary of State John Kerry ... Syngenta  scientist Mary-Dell Chilton , Ph.D., was ... Prize. The prize is the foremost international award recognizing ... quality, quantity or availability of food in the world. ... recognized for "revolutionary biotechnology discoveries that unlocked the key ...
(Date:6/19/2013)... 19, 2013 Clinverse, Inc. ... for clinical trials, today announced it will be ... (booth #2000) in Boston, June 24-26, 2013. ... and only fully configurable, cloud-based clinical financial lifecycle ... module within Clinverse’s eClinical Commerce Network, automates site ...
Breaking Biology Technology:Pfizer, GSK, and Siemens Form R&D Consortium With A*STAR's Institute of Chemical & Engineering Sciences 2Pfizer, GSK, and Siemens Form R&D Consortium With A*STAR's Institute of Chemical & Engineering Sciences 3Pfizer, GSK, and Siemens Form R&D Consortium With A*STAR's Institute of Chemical & Engineering Sciences 4City of Bellevue, Wash., Welcomes Assistive Technology Exhibit Hall 2Syngenta's Mary-Dell Chilton named 2013 World Food Prize laureate 2Clinverse, Inc. Exhibiting and Showcasing Its Technology at DIA 2013 2
... The firm's shares shot up 40% this morning after it ... drug in the company's pipeline, has been found to extend ... ,Late last week, new data and a regulatory decision buttressed ... - news - people ) is developing ...
... (WMC), Valhalla, New York, has selected Verisis developed by ... Corporation , for its new Cardiology Image and Information Management ... George E. Reed Heart Center , one of the ... east coast. The system will also extend into the ...
... of streaming media was predominantly targeted toward consumer applications ... money hasn't followed. The focus on streaming media is ... that can improve productivity and the information experience. Just ... educational institutions are beginning to see the value of ...
Cached Biology Technology:Genentech's Winning Streak 2Genentech's Winning Streak 3NY Medical Center Selects Camtronics for Cardiovascular Image and Information Management 2
(Date:6/19/2013)... of the patients who received injections of steroids ... New England Compounding Center has found that some ... not experience a worsening of their symptoms and ... infection, especially among those individuals who received injections ... along with an editorial by UC Davis Assistant ...
(Date:6/19/2013)... 2013 A study published in the Journal ... report of an oral probiotic supplement significantly increasing circulating ... The lead author on the study, Mitchell Jones, MD, ... from the New York Academy of Sciences and the ... Prebiotics, and the Host Microbiome: The Science of ...
(Date:6/19/2013)... Flemish plant scientist Marc Van Montagu (born 1933) is ... the American scientists Mary-Dell Chilton and Robert T. Fraley. ... the US Secretary of State, John Kerry. The World ... agriculture" - gives the award annually to one or ... importance for the quality, quantity or availability of food. ...
Breaking Biology News(10 mins):Evolution of an outbreak: Complications from contaminated steroid injections 2Study shows probiotic Lactobacillus reuteri NCIMB 30242 significantly increased vitamin D levels 2World Food Prize goes to a Belgian for the first time: The scientist Marc Van Montagu 2World Food Prize goes to a Belgian for the first time: The scientist Marc Van Montagu 3World Food Prize goes to a Belgian for the first time: The scientist Marc Van Montagu 4
... A specific biological response to cellular stress may predict ... common, non-invasive form of pre-malignant breast cancer-- ductal carcinoma ... could potentially be used in a clinical setting to ... therapy when initially diagnosed with DCIS, according to a ...
... Using an extremely sensitive measurement technique, researchers at ... a lead-specific DNAzyme uses the lock and key reaction ... the same DNAzyme uses the induced fit reaction ... and key mechanism explains why this particular lead-specific DNAzyme ...
... a new vaccine be the key to stopping Alzheimers ... Research Foundation (OMRF) shows that immunization could offer a ... disease. OMRF scientists immunized Alzheimers mice with a ... disease-causing process. The mice who received the vaccination showed ...
Cached Biology News:Cell response to stress signals predicts tumors in women with common pre-breast cancer 2Cell response to stress signals predicts tumors in women with common pre-breast cancer 3The key to unlocking the secret of highly specific DNAzyme catalysis 2An Alzheimer's vaccine? 2An Alzheimer's vaccine? 3
... The ISOQUANT(R) Isoaspartate Detection Kit is ... residues in proteins and peptides, which can ... asparagine or rearrangement of aspartic acid residues ... does not depend on the monitoring of ...
Request Info...
Rb anti-Occludin (C-term GST)...
Request Info...
Biology Products: